Excel Project 2
chandlerrosas
JohnsonJohnson.xlsxCompany Information
| ACCT 370 Excel Project | |
| Johnson & Johnson | |
| Company Information | |
| Company Name | Johnson & Johnson |
| Ticker Symbol | JNJ |
| Industry | Pharmaceuticals, Consumer products, Medical Devices |
| Products and Services Offered | Beauty, Over The Counter Pharmaceuticals, Baby Care, Oral Care, Women's Health, Wound Care |
| Immunology, Infectious Disease Vaccines, Neuroscience, Oncology, Cardiovascular Metabolic Diseases | |
| Orthopaedic, Surgery, Cardiovascular, Diabetes care, Vision Care | |
| Major Competitors | Pfizer, Merck, Proctor & Gamble, Bristol Myers Squibb, Unilever |
Historical Income Statements
| JOHNSON & JOHNSON AND SUBSIDIARIES | ||||||
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | ||||||
| At December 30, 2018 and December 30, 2017 | ||||||
| (Dollars in Millions) (Note 1) | ||||||
| 2018 | 2017 | 2016 | ||||
| Net earnings | $ | 15,297 | $ | 1,300 | $ | 16,540 |
| Other comprehensive income (loss), net of tax | ||||||
| Foreign currency translation | (1,518) | 1,696 | (612) | |||
| Securities: (1) | ||||||
| Unrealized holding gain (loss) arising during period | (1) | 159 | (52) | |||
| Reclassifications to earnings | 1 | (338) | (141) | |||
| Net change | 0 | (179) | (193) | |||
| Employee benefit plans: | ||||||
| Prior service credit (cost), net of amortization | (44) | 2 | 21 | |||
| Gain (loss), net of amortization | (56) | 29 | (862) | |||
| Effect of exchange rates | 92 | (201) | 159 | |||
| Net change | (8) | (170) | (682) | |||
| Derivatives & hedges: | ||||||
| Unrealized gain (loss) arising during period | (73) | (4) | (359) | |||
| Reclassifications to earnings | (192) | 359 | 110 | |||
| Net change | (265) | 355 | (249) | |||
| Other comprehensive income (loss) | (1,791) | 1,702 | (1,736) | |||
| Comprehensive income | $ | 13,506 | $ | 3,002 | $ | 14,804 |
Historical Balance Sheets
| JOHNSON & JOHNSON AND SUBSIDIARIES | ||||||
| CONSOLIDATED BALANCE SHEETS | ||||||
| At December 30, 2018 and December 30, 2017 | ||||||
| (Dollars in Millions Except Share and Per Share Amounts) (Note 1) | ||||||
| 2018 | 2017 | 2016 | ||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents (Notes 1 and 2) | $ | 18,107 | $ | 17,824 | $ | 18,972 |
| Marketable securities (Notes 1 and 2) | 1,580 | 472 | 22,935 | |||
| Accounts receivable trade, less allowances for doubtful accounts $248 (2017, $291) | 14,098 | 13,490 | 11,699 | |||
| Inventories (Notes 1 and 3) | 8,599 | 8,765 | 8,144 | |||
| Prepaid expenses and other receivables | 2,699 | 2,537 | 3,282 | |||
| Assets held for sale (Note 20) | 950 | 0 | 0 | |||
| Total current assets | 46,033 | 43,088 | 65,032 | |||
| Property, plant and equipment, net (Notes 1 and 4) | 17,035 | 17,005 | 15,912 | |||
| Intangible assets, net (Notes 1 and 5) | 47,611 | 53,228 | 26,876 | |||
| Goodwill (Notes 1 and 5) | 30,453 | 31,906 | 22,805 | |||
| Deferred taxes on income (Note 8) | 7,640 | 7,105 | 6,148 | |||
| Other assets | 4,182 | 4,971 | 4,435 | |||
| Total assets | $ | 152,954 | $ | 157,303 | $ | 141,208 |
| Liabilities and Shareholders’ Equity | ||||||
| Current liabilities | ||||||
| Loans and notes payable (Note 7) | 2,796 | 3,906 | 4,684 | |||
| Accounts payable | 7,537 | 7,310 | 6,918 | |||
| Accrued liabilities | 7,601 | 7,304 | 5,635 | |||
| Accrued rebates, returns and promotions | 9,380 | 7,210 | 5,403 | |||
| Accrued compensation and employee related obligations | 3,098 | 2,953 | 2,676 | |||
| Accrued taxes on income (Note 8) | 818 | 1,854 | 971 | |||
| Total current liabilities | 31,230 | 30,537 | 26,287 | |||
| Long-term debt (Note 7) | 27,684 | 30,675 | 22,442 | |||
| Deferred taxes on income (Note 8) | 7,506 | 8,368 | 2,910 | |||
| Employee related obligations (Notes 9 and 10) | 9,951 | 10,074 | 9,615 | |||
| Long-term taxes payable (Note 8) | 8,242 | 8,472 | 9,536 | |||
| Other liabilities | 8,589 | 9,017 | 0 | |||
| Total liabilities | 93,202 | 97,143 | 70,790 | |||
| Shareholders’ equity | ||||||
| Preferred stock — without par value (authorized and unissued 2,000,000 shares) | 0 | 0 | 0 | |||
| Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120 | 3,120 | 3,120 | |||
| Accumulated other comprehensive income (loss) (Note 13) | (15,222) | (13,199) | (14,901) | |||
| Retained earnings | 106,216 | 101,793 | 110,551 | |||
| 94,114 | 91,714 | 98,770 | ||||
| Less: common stock held in treasury, at cost (Note 12) (457,519,000 shares and 437,318,000 shares) | 34,362 | 31,554 | 28,352 | |||
| Total shareholders’ equity | 59,752 | 60,160 | 70,418 | |||
| Total liabilities and shareholders’ equity | $ | 152,954 | $ | 157,303 | $ | 141,208 |
Historical Statement of Cash Fl
| JOHNSON & JOHNSON AND SUBSIDIARIES | ||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
| At December 30, 2018 and December 30, 2017 | ||||||
| (Dollars in Millions) (Note 1) | ||||||
| 2018 | 2017 | 2016 | ||||
| Cash flows from operating activities | ||||||
| Net earnings | $ | 15,297 | $ | 1,300 | $ | 16,540 |
| Adjustments to reconcile net earnings to cash flows from operating activities: | ||||||
| Depreciation and amortization of property and intangibles | 6,929 | 5,642 | 3,754 | |||
| Stock based compensation | 978 | 962 | 878 | |||
| Asset write-downs | 1,258 | 795 | 283 | |||
| Gain on sale of assets/businesses | (1,217) | (1,307) | (563) | |||
| Deferred tax provision | (1,016) | 2,406 | (341) | |||
| Accounts receivable allowances | (31) | 17 | (11) | |||
| Changes in assets and liabilities, net of effects from acquisitions and divestitures: | ||||||
| Increase in accounts receivable | (1,185) | (633) | (1,065) | |||
| (Increase)/Decrease in inventories | (644) | 581 | (249) | |||
| Increase in accounts payable and accrued liabilities | 3,951 | 2,725 | 656 | |||
| Increase in other current and non-current assets | (275) | (411) | (529) | |||
| (Decrease)/Increase in other current and non-current liabilities | (1,844) | 8,979 | (586) | |||
| Net cash flows from operating activities | 22,201 | 21,056 | 18,767 | |||
| Cash flows from investing activities | ||||||
| Additions to property, plant and equipment | (3,670) | (3,279) | (3,226) | |||
| Proceeds from the disposal of assets/businesses, net | 3,203 | 1,832 | 1,267 | |||
| Acquisitions, net of cash acquired (Note 20) | (899) | (35,151) | (4,509) | |||
| Purchases of investments | (5,626) | (6,153) | (33,950) | |||
| Sales of investments | 4,289 | 28,117 | 35,780 | |||
| Other (primarily intangibles) | (464) | (234) | (123) | |||
| Net cash used by investing activities | (3,167) | (14,868) | (4,761) | |||
| Cash flows from financing activities | ||||||
| Dividends to shareholders | (9,494) | (8,943) | (8,621) | |||
| Repurchase of common stock | (5,868) | (6,358) | (8,979) | |||
| Proceeds from short-term debt | 80 | 869 | 111 | |||
| Retirement of short-term debt | (2,479) | (1,330) | (2,017) | |||
| Proceeds from long-term debt, net of issuance costs | 5 | 8,992 | 12,004 | |||
| Retirement of long-term debt | (1,555) | (1,777) | (2,223) | |||
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | 949 | 1,062 | 1,189 | |||
| Other | (148) | (188) | (15) | |||
| Net cash used by financing activities | (18,510) | (7,673) | (8,551) | |||
| Effect of exchange rate changes on cash and cash equivalents | (241) | 337 | (215) | |||
| Increase/(Decrease) in cash and cash equivalents | 283 | (1,148) | 5,240 | |||
| Cash and cash equivalents, beginning of year (Note 1) | 17,824 | 18,972 | 13,732 | |||
| Cash and cash equivalents, end of year (Note 1) | $ | 18,107 | $ | 17,824 | $ | 18,972 |
| Supplemental cash flow data | ||||||
| Cash paid during the year for: | ||||||
| Interest | 1,049 | 960 | 730 | |||
| Interest, net of amount capitalized | 963 | 866 | 628 | |||
| Income taxes | 4,570 | 3,312 | 2,843 | |||
